1832 Asset Management L.P. Alnylam Pharmaceuticals, Inc. Transaction History

1832 Asset Management L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $93,069 - $115,349	545 New	545 $96,000
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $4.11 Million - $4.71 Million	-22,200 Reduced 97.6%	545 $103,000
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $67.3 Million - $86.8 Million	-368,600 Reduced 94.19%	22,745 $4.56 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $779,226 - $1.01 Million	4,200 Added 1.08%	391,345 $93 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $53.6 Million - $89.7 Million	386,600 Added 70935.78%	387,145 $77.5 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $69,313 - $94,780	545 New	545 $88,000
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $2.18 Million - $3.27 Million	-20,900 Closed	0 $0
Q1 2020 May 26, 2020	BUY	$93.12 - $133.99 $1.95 Million - $2.8 Million	20,900 New	20,900 $2.29 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.